Mucosal disease activity may predict response to fecal microbiota transplantation in patients with ulcerative colitis.

COI Statement

Competing interests: The authors declare no competing interests. Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work the author(s) used ChatGPT in order to decrease word count, and improve language and readability. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication

References:

• Nguyen, G. C., Chong, C. A. & Chong, R. Y. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J. Crohns Colitis 8, 288–295 (2014).
• Ihekweazu, F. D. et al. Progression to colectomy in the era of biologics: a single center experience with pediatric ulcerative colitis. J. Pediatr. Surg. 55, 1815–1823 (2020).
• Van Limbergen, J. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135, 1114–1122 (2008).
• Kellermayer, R. Fecal microbiota transplantation: great potential with many challenges. Transl. Gastroenterol. Hepatol. 4, 40 (2019).
• Caenepeel, C. et al. Rigorous donor selection for fecal microbiota transplantation in active ulcerative colitis: key lessons from a randomized controlled trial halted for futility. Clin. Gastroenterol. Hepatol. 23, 621–631 e627 (2025).